GenMark Diagnostics (GNMK) Warns for FY2013
Tweet
Share
E-mailGet Alerts GNMK Hot Sheet
Join SI Premium – FREE
GenMark Diagnostics (NASDAQ: GNMK) updated its annual revenue guidance for the year ending December 31, 2013. As a result of additional uncertainties relating to the future revenue contribution from its largest customer, together with persisting reimbursement and other challenges affecting the emerging pharmacogenomics market sector, the Company is updating its annual revenue guidance to approximately $30 million from its original estimate of approximately $35 million.
The Wall Street consensus is $35.1 million.
"Our core business continues to exceed our expectations, with new customers, increasing placements of new analyzers and expanded menu utilization," stated GenMark's President & CEO Hany Massarany. "As previously communicated, we remained prudently cautious regarding the future revenue contribution from the pharmacogenomics sector, including our single largest customer. In light of the recent developments which introduced additional uncertainty regarding this customer, we have taken a more conservative outlook and reduced our revenue expectations for the remainder of the year," Massarany further stated. “Nevertheless, we believe the significant growth rates we are experiencing in our core business strengthen our position and support year-over-year growth of about 50%, resulting in approximately $30 million of annual revenue. Furthermore, we continue to make excellent progress toward the development of our NexGen sample-to-answer system, which we believe will fuel significant growth and our future success as a global leader in molecular diagnostics.”
The Wall Street consensus is $35.1 million.
"Our core business continues to exceed our expectations, with new customers, increasing placements of new analyzers and expanded menu utilization," stated GenMark's President & CEO Hany Massarany. "As previously communicated, we remained prudently cautious regarding the future revenue contribution from the pharmacogenomics sector, including our single largest customer. In light of the recent developments which introduced additional uncertainty regarding this customer, we have taken a more conservative outlook and reduced our revenue expectations for the remainder of the year," Massarany further stated. “Nevertheless, we believe the significant growth rates we are experiencing in our core business strengthen our position and support year-over-year growth of about 50%, resulting in approximately $30 million of annual revenue. Furthermore, we continue to make excellent progress toward the development of our NexGen sample-to-answer system, which we believe will fuel significant growth and our future success as a global leader in molecular diagnostics.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
Create E-mail Alert Related Categories
Guidance, Hot Guidance, Management CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
